(114 days)
No
The document describes a physical accessory for CPAP machines and does not mention any software, algorithms, or data processing that would indicate the use of AI/ML.
No.
A therapeutic device directly treats a condition or disease. This device is an accessory to a CPAP machine, which is the therapeutic device for sleep apnea. The nasal interface itself does not provide the therapy.
No
The device is described as an "accessory device to CPAP machines in the treatment of obstructive sleep apnea (OSA)" and an "accessory intended for use with devices that deliver Continuous Positive Airway Pressure (CPAP)." It delivers therapy (air pressure) but does not gather information or make a diagnosis.
No
The device description explicitly lists physical components such as a plastic manifold, nasal mask cushion, nasal pillows, adjustable headgear straps, and an interface tube, indicating it is a hardware device.
Based on the provided information, the BreatheX Nasal Interface System is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use clearly states it's an accessory device for CPAP machines used in the treatment of obstructive sleep apnea. This involves delivering air pressure to a patient's airway, which is a therapeutic function, not a diagnostic one.
- Device Description: The description details a physical interface system (mask, pillows, headgear, tube) designed to connect to a CPAP machine. It doesn't mention any components or functions related to analyzing biological samples (blood, urine, tissue, etc.) or providing diagnostic information.
- Lack of Diagnostic Function: The device's purpose is to facilitate the delivery of therapy (CPAP), not to diagnose a condition or provide information about a patient's health status based on in vitro analysis.
IVD devices are specifically designed to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The BreatheX Nasal Interface System does not perform any such function.
N/A
Intended Use / Indications for Use
The BreatheX Nasal Interface System is intended for use as accessory device to CPAP machines in the treatment of obstructive sleep apnea (OSA).
The BreatheX Nasal Interface System is for use on adult spontaneously breathing (non-ventilator dependant) patients at home or in the sleep clinic.
The BreatheX Nasal Interface System is an accessory intended for use with devices that deliver Continuous Positive Airway Pressure (CPAP) and bi-level positive airway pressure in treating adult patients.
Product codes
BZD
Device Description
The BreatheX Nasal Interface System has been designed for use as an accessory with commonly marketed CPAP units. The device consists of a plastic manifold with integral exhaust port, nasal mask cushion, a set of nasal pillows, adjustable headgear straps, and an interface tube with a 22mm fitting.
The Nasal Interface System allows a patient to use either the nasal pillows or nasal mask cushion interchangeably. The lightweight construction of the device is designed to maximize patient comfort.
The device is labeled for single patient use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Adult
Intended User / Care Setting
Home or in the sleep clinic
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Tests Submitted:
The device was tested in accordance with applicable standards for medical device environmental temperature and humidity, shock and vibration, and moisture ingress. The BreatheX Nasal Interface System passed all of the tests.
Static and dynamic performance testing was conducted in comparison with the predicate devices for dead space, pressure-flow characteristics and sound output level. The device met specified requirements and was comparable to the applicable specifications of the predicate devices.
The materials utilized in the device comply with biocompatibility requirements appropriate for the intended use.
Risk and Hazard analyses were performed, and the results of the analyses demonstrated that the residual risks were acceptable for the intended use.
Clinical Tests Submitted: None
The function of the BreatheX Nasal Interface System is substantially equivalent to the predicate devices. Laboratory and standards compliance tests are provided to support the safety and performance of the device.
As described above, all of the testing demonstrates that the Hoffman Laboratories BreatheX Nasal Interface System is as safe and effective and performs in a manner equivalent to the predicate nasal interface devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 868.5905 Noncontinuous ventilator (IPPB).
(a)
Identification. A noncontinuous ventilator (intermittent positive pressure breathing-IPPB) is a device intended to deliver intermittently an aerosol to a patient's lungs or to assist a patient's breathing.(b)
Classification. Class II (performance standards).
0
AUG 1 1 2006
Summary of Safety and Effectiveness in accordance with 21 CFR 807.92
Company Name: Hoffman Laboratories, LLC 9305 Eton Ave Chatsworth CA 91311
Contact: Keith Bosecker, President
Phone: 818-341 4131
Fax: 818-341 4135
Email: keith_bosecker@hoffmanlaboratories.com
Summary Date: April 14, 2006
Trade Name: Hoffman Laboratories BreatheX™ Nasal Interface System
Common Name: CPAP Device Accessory
Common Classification/Name: Ventilator, non-continuous, non-life supporting
Product Code(s): 21 CFR 868.5905 BZD
Class: Class II
Predicate Devices:
- 510K Number: K031883 ●
- Manufacturer: SensorMedics Corporation (VIASYS) .
- Lyra Nasal Interface . Trade Name:
- 510K Number: K050359 .
- Manufacturer: ResMed Limited .
- Ultra Mirage II Mask Trade Name: ●
Reason for Submission: New Device
1
Description of Device
The BreatheX Nasal Interface System has been designed for use as an accessory with commonly marketed CPAP units. The device consists of a plastic manifold with integral exhaust port, nasal mask cushion, a set of nasal pillows, adjustable headgear straps, and an interface tube with a 22mm fitting.
The Nasal Interface System allows a patient to use either the nasal pillows or nasal mask cushion interchangeably. The lightweight construction of the device is designed to maximize patient comfort.
The device is labeled for single patient use.
Intended Use
The BreatheX Nasal Interface System is intended for use as accessory device to CPAP machines in the treatment of obstructive sleep apnea (OSA).
The BreatheX Nasal Interface System is for use on adult spontaneously breathing (non-ventilator dependant) patients at home or in the sleep clinic.
Indications for Use
The BreatheX Nasal Interface System is an accessory intended for use with devices that deliver Continuous Positive Airway Pressure (CPAP) and bi-level positive airway pressure in treating adult patients.
Caution: Federal law restricts this device to sale by or on the order of a physician.
Technology
The BreatheX Nasal Interface device utilizes similar technological characteristics as the predicate devices. All devices utilize a rigid plastic manifold with a soft silicone rubber seal to the area around the nose or the nasal passages. All devices are attached to the patient's head using flexible adjustable straps.
Like the predicate devices, the manifold of the BreatheX Nasal Interface System has an integral exhaust port which continuously vents a portion of the CPAP treatment air in order to minimize the rebreathing of expired gases.
2
Non-Clinical Tests Submitted:
The device was tested in accordance with applicable standards for medical device environmental temperature and humidity, shock and vibration, and moisture ingress. The BreatheX Nasal Interface System passed all of the tests.
Static and dynamic performance testing was conducted in comparison with the predicate devices for dead space, pressure-flow characteristics and sound output level. The device met specified requirements and was comparable to the applicable specifications of the predicate devices.
The materials utilized in the device comply with biocompatibility requirements appropriate for the intended use.
Risk and Hazard analyses were performed, and the results of the analyses demonstrated that the residual risks were acceptable for the intended use.
Clinical Tests Submitted: None
Conclusions
The function of the BreatheX Nasal Interface System is substantially equivalent to the predicate devices. Laboratory and standards compliance tests are provided to support the safety and performance of the device.
As described above, all of the testing demonstrates that the Hoffman Laboratories BreatheX Nasal Interface System is as safe and effective and performs in a manner equivalent to the predicate nasal interface devices.
3
Image /page/3/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, with three intertwined lines representing the branches of government. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES . USA" is arranged in a circular pattern around the caduceus. The seal is black and white.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 1 1 2006
Mr. Keith Bosecker President Hoffman Laboratories, LLC 9305 Eton Avenue Chatsworth, California 91311
Re: K061099
Trade/Device Name: Hoffman Laboratories BreatheXTM Nasal Interface System Regulation Number: 868.5905 Regulation Name: Noncontinuous Ventilator (IPPB) Regulatory Class: II Product Code: BZD Dated: August 3, 2006 Received: August 7, 2006
Dear Mr. Bosecker:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the federal Register.
4
Page 2 - Mr. Bosecker
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrlv/industry/support/index.html.
Sincerely yours,
Smitte Y. Michie Davis
Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number (if known):
Hoffman Laboratories BreatheX™ Nasal Interface System Device Name:
Indications for use:
The BreatheX Nasal Interface System is an accessory intended for use with devices that deliver Continuous Positive Airway Pressure (CPAP) and bi-level positive airway pressure in treating adult patients.
Caution: Federal law restricts this device to sale by or on the order of a physician.
Prescription Use __ × (Part 21 CFR 801 Subpart D) AND / OR
Over-The-Counter Use _ (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Sua Rump
ion of Anestheaningy General Hospital, Control, Dental Devices
) Number. K061099
Page 1 of _1 _